This group of cancer therapy drugs have previously been shown to not only impact amyloid formation by inhibiting αSyn kinases (such as C‐Abl) and promote degradation in vivo but also improve motor neuron activity in α‐synucleinopathy models 30, 31, 32. Here, ABL1 is linked to cancer.